Span poly-L-arginine nanoparticles are efficient non-viral vectors for PRPF31 gene delivery: An approach of gene therapy to treat retinitis pigmentosa

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 8, 2016, Pages 2251-2260

  Pensado, Andrea ^a   Diaz Corrales, Francisco J ^b   De la Cerda, Berta ^b   Valdés Sánchez, Lourdes ^b   del Boz, Ana Aramburu ^b   Rodriguez Martinez, Daniel ^b   García Delgado, Ana B ^b   Seijo, Begoña ^a,c   Bhattacharya, Shomi S ^b   Sanchez, Alejandro ^a,c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CABIMER Andalusian Center for Molecular Biology and Regenerative Medicine CSIC University of Seville UPO   (Spain)

^c Instituto de Investigación Sanitaria de Santiago de Compostela IDIS   (Spain)

Author keywords

Gene therapy; Nanoparticle; Ophthalmology; Retinitis pigmentosa; Span

Indexed keywords

ALDEHYDES; AMINO ACIDS; GENE TRANSFER; GENES; MAMMALS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; OPHTHALMOLOGY; OPTICAL TOMOGRAPHY;

AUTOSOMAL DOMINANTS; ELECTRORETINOGRAMS; GENE DELIVERY; NONVIRAL VECTORS; POINT MUTATIONS; RETINITIS PIGMENTOSA; SPAN; VISUAL ACUITY;

GENE THERAPY;

GREEN FLUORESCENT PROTEIN; NANOPARTICLE; PARVOVIRUS VECTOR; POLYARGININE; PRE MRNA PROCESSNG FACTOR 31; PROTEIN; SORBITAN OLEATE; UNCLASSIFIED DRUG; ARGININE; EYE PROTEIN; PRPF31 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; ELECTRORETINOGRAM; EYE EXAMINATION; GENE; GENE THERAPY; GENETIC TRANSFECTION; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; OPTOMOTOR TEST; PLASMID; POINT MUTATION; PROTEIN EXPRESSION; PRPF31 GENE; RETINAL THICKNESS; RETINITIS PIGMENTOSA; STATISTICAL SIGNIFICANCE; VISUAL ACUITY; ANIMAL; DNA MUTATIONAL ANALYSIS; DOMINANT GENE; HUMAN; MUTATION; PEDIGREE; PROCEDURES;

ANIMALS; ARGININE; DNA MUTATIONAL ANALYSIS; EYE PROTEINS; GENES, DOMINANT; GENETIC THERAPY; HUMANS; MICE; MUTATION; NANOPARTICLES; PEDIGREE; RETINITIS PIGMENTOSA;

EID: 84983761052     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.06.007     Document Type: Article

References (43)

1. 1 Vithana, EN, Abu-Safieh, L, Allen, MJ, Carey, A, Papaioannou, M, Chakarova, C, et al. A Human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). Mol. Cell 8 (2001), 375–381.
2. 2 Hartong, DT, Berson, EL, Dryja, TP, Retinitis pigmentosa. Lancet 368 (2006), 1795–1809.
3. 3 Wang, DY, Chan, WM, Tam, POS, Baum, L, Lam, DSC, Chong, KKL, et al. Gene mutations in retinitis pigmentosa and their clinical implications. Clin Chim Acta 351 (2005), 5–16.
4. 4 Phelan, JK, Bok, D, A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes. Mol Vis 6 (2000), 116–124.
5. 5 Farrar, GJ, Kenna, PF, Humphries, P, On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J 21 (2002), 857–864.
6. 6 RetNet, Retinal Information Network. 2016 [Available at: https://sph.uth.edu/retnet/home.htm. Accessed January 2, 2016].
7. 7 Linder, B, Hirmer, A, Gal, A, Rüther, K, Bolz, HJ, Winkler, C, et al. Identification of a PRPF4 loss-of-function variant that abrogates U4/U6.U5 tri-snRNP integration and is associated with retinitis pigmentosa. PLoS One, 9, 2014, e111754.
8. 8 Waseem, NH, Vaclavik, V, Webster, A, Jenkins, SA, Bird, AC, Bhattacharya, SS, Mutations in the gene coding for the pre-mRNA splicing factor, PRPF31, in patients with autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 48 (2007), 1330–1334.
9. 9 Fischer, A, Hacein-Bey-Abina, S, Cavazzana-Calvo, M, 20 years of gene therapy for SCID. Nat Immunol 11 (2010), 457–460.
10. 10 Cartier, N, Aubourg, P, Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol 20 (2010), 857–862.
11. 11 LeWitt, PA, Rezai, AR, Leehey, MA, Ojemann, SG, Flaherty, AW, Eskandar, EN, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 10 (2011), 309–319.
12. 12 Bainbridge, JW, Smith, AJ, Barker, SS, Robbie, S, Henderson, R, Balaggan, K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 (2008), 2231–2239.
13. 13 Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr., Mingozzi, F, Bennicelli, J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 (2008), 2240–2248.
14. 14 Testa, F, Maguire, AM, Rossi, S, Pierce, EA, Melillo, P, Marshall, K, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology 120 (2013), 1283–1291.
15. 15 Colella, P, Cotugno, G, Auricchio, A, Ocular gene therapy: current progress and future prospects. Trends Mol Med 15 (2009), 23–31.
16. 16 Chaum, E, Hatton, MP, Gene therapy for genetic and acquired retinal diseases. Surv Ophthalmol 47 (2002), 449–469.
17. 17 Zhang, W, Solanki, M, Muther, N, Ebel, M, Wang, J, Sun, C, et al. Hybrid adeno-associated viral vectors utilizing transposase-mediated somatic integration for stable transgene expression in human cells. PLoS One, 8, 2013, e76771.
18. 18 Vannucci, L, Lai, M, Chiuppesi, F, Ceccherini-Nelli, L, Pistello, M, Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 36 (2013), 1–22.
19. 19 Bennicelli, J, Wright, JF, Komaromy, A, Jacobs, JB, Hauck, B, Zelenaia, O, et al. Reversal of blindness in animal models of Leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther 16 (2008), 458–465.
20. 20 Bennett, J, Maguire, AM, Cideciyan, AV, Schnell, M, Glover, E, Anand, V, et al. Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. Proc Natl Acad Sci U S A 96 (1999), 9920–9925.
21. 21 Guy, J, Qi, X, Muzyczka, N, Hauswirth, WW, Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthalmol 117 (1999), 929–937.
22. 22 Allocca, M, Doria, M, Petrillo, M, Colella, P, Garcia-Hoyos, M, Gibbs, D, et al. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest 118 (2008), 1955–1964.
23. 23 Greenberg, B, Butler, J, Felker, GM, Ponikowski, P, Voors, AA, Pogoda, JM, et al. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. Gene Ther 23 (2016), 313–319.
24. 24 Wang, M, Crosby, A, Hastie, E, Samulski, JJ, McPhee, S, Joshua, G, et al. Prediction of adeno-associated virus neutralizing antibody activity for clinical application. Gene Ther 22 (2015), 984–992.
25. 25 Conley, SM, Naash, MI, Nanoparticles for retinal gene therapy. Prog Retin Eye Res 29 (2010), 376–397.
26. 26 Wasungu, L, Hoekstra, D, Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release 116 (2006), 255–264.
27. 27 Pensado, A, Seijo, B, Sanchez, A, Current strategies for DNA therapy based on lipid nanocarriers. Expert Opin Drug Deliv 11 (2014), 1721–1731.
28. 28 Bloquel, C, Bourges, J, Touchard, E, Berdugo, M, BenEzra, D, Behar-Cohen, F, Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev 58 (2006), 1224–1242.
29. 29 Pensado, A, Fernandez-Piñeiro, I, Seijo, B, Sanchez, A, Anionic nanoparticles based on Span 80 as low-cost, simple and efficient non-viral gene-transfection systems. Int J Pharm 476 (2014), 23–30.
30. 30 Sanchez, A, Seijo, B, Zorzi, GK, Carvalho, ES, Pensado, A, inventors, Nanoparticulate systems prepared from sorbitan esters. 2013 [WO2013068625 A1].
31. 31 Pensado, A, Martín-Pastor, M, Zorzi, GK, Carvalho, ES, Sanchez, A, Structural analysis of nanosystems: solid sorbitan esters nanoparticles (SSN) as a case study. Eur J Pharm Biopharm 104 (2016), 189–199.
32. 32 Valdes-Sanchez, L, De la Cerda, B, Diaz-Corrales, FJ, Massalini, S, Chakarova, CF, Wright, AF, et al. ATR localizes to the photoreceptor connecting cilium and deficiency leads to severe photoreceptor degeneration in mice. Hum Mol Genet 22 (2013), 1507–1515.
33. 33 Prusky, GT, Alam, NM, Beekman, S, Douglas, RM, Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci 45 (2004), 4611–4616.
34. 34 Mihelec, M, Pearson, RA, Robbie, SJ, Buch, PK, Azam, SA, Bainbridge, JW, et al. Long-term preservation of cones and improvement in visual function following gene therapy in a mouse model of Leber congenital amaurosis caused by guanylate cyclase-1 deficiency. Hum Gene Ther 22 (2011), 1179–1190.
35. 35 Uthra, S, Kumaramanickavel, G, Gene therapy in ophthalmology. Oman J Ophthalmol 2 (2009), 108–110.
36. 36 Li, X, Li, W, Dai, X, Kong, F, Zheng, Q, Zhou, X, et al. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse: a model for midcourse RPE65 Leber congenital amaurosis. Invest Ophthalmol Vis Sci 52 (2011), 7–15.
37. 37 Bejjani, RA, BenEzra, D, Cohen, H, Rieger, J, Andrieu, C, Jeanny, J, et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol Vis 11 (2005), 124–132.
38. 38 Farjo, R, Skaggs, J, Quiambao, AB, Cooper, MJ, Naash, MI, Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS One, 1, 2006, e38.
39. 39 Andrieu-Soler, C, Bejjani, R, de Bizemont, T, Normand, N, BenEzra, D, Behar-Cohen, F, Ocular gene therapy: a review of nonviral strategies. Mol Vis 12 (2006), 1334–1347.
40. 40 Diaz-Corrales, F, De la Cerda, B, Valdes-Sanchez, L, Rodriguez-Martinez, D, Aramburu, A, Rodriguez-Bocanegra, E, et al. Degenerative phenotype observed in retinal pigment epithelium of Prpf31A216P/+ mice is caused by an abnormal pre-mRNA splicing of Rpe65 gene. Invest Ophthalmol Vis Sci, 56, 2015, 5400.
41. 41 Graziotto, JJ, Farkas, MH, Bujakowska, K, Deramaudt, BM, Zhang, Q, Nandrot, EF, et al. Three gene-targeted mouse models of RNA splicing factor RP show late-onset RPE and retinal degeneration. Invest Ophthalmol Vis Sci 52 (2011), 190–198.
42. 42 Hiramatsu, N, Chiang, W, Kurt, TD, Sigurdson, CJ, Lin, JH, Multiple mechanisms of unfolded protein response-induced cell death. Am J Pathol 185 (2015), 1800–1808.
43. 43 Bujakowska, K, Maubaret, C, Chakarova, CF, Tanimoto, N, Beck, SC, Fahl, E, et al. Study of gene-targeted mouse models of splicing factor gene Prpf31 implicated in human autosomal dominant retinitis pigmentosa (RP). Invest Ophthalmol Vis Sci 50 (2009), 5927–5933.